The most widely studied strategy for OX40L is OX40 agonist therapy.Preclinical studies demonstrate that OX40 agonists, whether used as monotherapy or in combination, elicit robust antitumor activity in murine tumor models. The gene discussed is TNFSF4; the disease is neoplasm.